Interview Timeframes Conduct a minimum of 2 interviews: 1st interview

Slides:



Advertisements
Similar presentations
Contact Evaluation Your name Institution/organization Meeting Date International Standards 18, 19.
Advertisements

National Tuberculosis Controllers Association
Using the Supervisory Checklist Module 9 Part B. How do I monitor? The supervisory checklist gives you a structure you can use … … but it should not limit.
Tuberculosis in Children: Prevention Module 10C - March 2010.
USAPHC, Army Public Health Nursing Staff Officer
TB Contact Investigation
Mortality Among a Tuberculosis Outbreak Los Angeles County, 2007–2013 Brian Baker, MD Amit Chitnis, MD MPH Leslie Henry, BSN RN PHN 48th CTCA Educational.
World Health Organization TB Case Definitions
Why do we test? 1.We want to prevent an outbreak of Tuberculosis in our campus community 2.We want to find those that are affected and get them treated.
Diagnosis of TB.
Module 10: Understanding Laboratory Data *Image courtesy of: World Lung Foundation.
Cost-Conscious Care Presentation Follow-up Chest X-Ray in Patients Admitted for Community Acquired Pneumonia Huy Tran, PGY-2 12/12/2013.
Culture Conversion and Self- Administered Therapy in Privately Managed Tuberculosis Patients Melissa Ehman MPH, Jennifer Flood MD MPH, Pennan Barry MD.
Current international guidelines recommend 6–9 months of isoniazid (INH) preventive chemotherapy to prevent the development of active tuberculosis in.
1385 / 5 / 15 نشست سالانه برنامه كنترل سل شهريور Tuberculosis & Air Travel.
Evaluating Tuberculosis Surveillance and Action in an Urban and Rural Setting Kristine Lykens, Ph.D. In collaboration with Anita Kurian, MPH, MBBS Patrick.
Update on Tuberculosis contact investigation
Tuberculosis Research of INA-RESPOND on Drug-resistant
LESSON 9.5: TYPES OF STUDIES Module 9: Epidemiology Obj. 9.5: Compare & contrast different types of epidemiological studies.
Elements of the Cohort Review Approach Harvey L. Marx, Jr. Lisa Schutzenhofer TB Program Controller TB Program Manager.
I AM NOT HOMELESS CSTE JUNE 2013 Dee Pritschet, TB Controller – North Dakota Department of Health Shawn McBride, Epidemiologist – North Dakota Department.
Surveillance Data in Action: Tuberculosis Indicators Melissa Ehman, MPH Tuberculosis Control Branch (TBCB) Division of Communicable Disease Control Center.
Cluster Interview Template Updated 04/2013. Introduction to the Training ● The slides will first show a picture of the section of the template that will.
CDC Guidelines for Use of QuantiFERON ® -TB Gold Test Philip LoBue, MD Centers for Disease Control and Prevention Division of Tuberculosis Elimination.
Comprehensive Field Record. Introduction to the Training ● The slides will first show a picture of the section of the template that will be discussed.
NAAT Is it Time for a New Option in California?. Background CDC 2009 guidelines recommend NAAT for each patient with suspected TB for whom the test result.
By: Mpho Kontle and Topo Moses. Introduction & Etiology Multi-drug-resistant tuberculosis (MDR-TB) is defined as tuberculosis that is resistant to at.
Investigation of Contacts of Persons with Infectious Tuberculosis, 2005 Division of Tuberculosis Elimination Centers for Disease Control and Prevention.
Severe Acute Respiratory Syndrome (SARS) and Preparedness for Biological Emergencies 27 April 2004 Jeffrey S. Duchin, M.D. Chief, Communicable Disease.
Introduction to Contact Investigation Process Amy Schmitt, BSN, RN Public Health Grand Rounds Tuberculosis November 19, 2015.
Ebola preparedness and Response in Lao PDR. Outline Objective The preparedness contingency plan Phase 1: Preparedness Phase 2: Contingency for response.
TB Prevention and Control in Correctional and Detention Facilities Mark Lobato, MD Division of TB Elimination Centers for Disease Control and Prevention.
Case Discussion 2 - TB IN CHILDREN by Dr. Jeyaseelan P. Nachiappan & Dr. Suryati Adnan 1 Picture of CPG Cover.
Empirical Treatment of Community-Acquired Pneumonia and the Development of Fluoroquinolone-Resistant Tuberculosis Clinical Infectious Diseases 2009; 48:1354–60.
Epidemiology of Human Infections with Avian Influenza A(H7N9) Virus in China Qun Li, M.D., Lei Zhou, M.D., Minghao Zhou, Ph.D., Zhiping Chen, M.D., Furong.
Emerging Infectious Disease Tabletop Exercise
Maternal Toxicity Management
Outbreak Investigation
Understanding Epidemiology
Transmission and Pathogenesis
Management of the Newborn When Maternal TB Suspected
The story of Munya* (and us)
TB CASE MANAGEMENT CONFERENCE
Whole-Genome Sequencing; It’s Not Just For Epis
Guidance on completion of Isoniazid Preventive Therapy register
Infection Control Q and A APIC Greater NY Chapter 13 May 17, 2017 Beth Nivin BA MPH NYC DOHMH Communicable Disease Program
Infant born with mother Tuberculosis
Outbreak Investigations
This is an archived document.
Maternal Toxicity Management
Maternal Toxicity Management
Introduction to Clinical Pharmacy
R Nagar 1, Debashish Kundu2, S Chandra2 , A Khanna1
Coagulation Screening In Elective & Emergency General Surgery
Nucleic Acid Amplification Test for Tuberculosis
Time to update guidelines on screening for latent tuberculosis infection in dermatologic patients being treated with tumor necrosis factor-alfa inhibitors 
CDC Guidelines for Use of QuantiFERON®-TB Gold Test
Presentation 10 Analysing results and defining cases
Sarah Siddiqui, MD, MPH University of Texas Medical Branch
Mark Lobato, MD Division of TB Elimination
Tolerability of Isoniazid Preventive therapy Among HIV infected Cohort in Nigeria Folajinmi Oluwasina Strategic Information Unit AIDS Healthcare Foundation,
Time to update guidelines on screening for latent tuberculosis infection in dermatologic patients being treated with tumor necrosis factor-alfa inhibitors 
Background 1  § About 1/3 of world population infected with Tuberculosis (TB) § 25% of all avoidable deaths in developing countries due to TB.
Coordinate Operations Standard
Cheng shiming National TB Center in China May,3, 2004
Using Whole Genome Sequencing Analysis in California
Introduction to Effective Contact Investigation Strategies
Perspectives from Los Angeles County Tuberculosis Control Program
Common Rule Updates Tips and Tricks
5th edition NTP MANUAL OF PROCEDURES Case Finding
Presentation transcript:

Interview Timeframes Conduct a minimum of 2 interviews: 1st interview ≤ 1 business day of reporting for infectious patients ≤ 3 business days for others 2nd interview: 1–2 weeks later Conduct additional interviews as needed Slide Notes: Review slide: Related to 1st interview sub-bullet ask the group to share “Which cases do we consider infectious?” It’s a rare event to get and give all the information you need to in one interview should plan from the start that there will be multiple interview interactions with the patient. All interviews should be done in person, especially the initial IX. (only use the phone if time is short, or you only need very little info) Interviews provide chances to check-in to see how the patient is doing, clinically and emotionally

Estimating Onset of the Infectious Period Characteristic TB symptoms AFB sputum smear positive Cavitary chest radiograph Recommended minimum beginning of likely period of infectiousness Yes No 3 months before symptom onset or 1st positive findings consistent with TB disease, whichever is longer 3 months before 1st positive finding consistent with TB disease 4 weeks before date of suspected diagnosis Slide Notes: Determining an “infectious period” focuses the investigation on those who are at greatest risk for having become infected. It’s important to make sure all team members involved in the care of the TB patient and in the associated contact investigation are aware of the determined infectious period. DOCUMENT THE IP, and if updated after pt. Ix, redocument Refer participants to handout 4 :Estimating Onset of IP This is a modification of a table that guides the estimation of onset of infectiousness based on 3 key characteristics of the TB case which include: the presence or absence of symptoms, sputum smear status and whether the patient has cavitary disease on chest X-ray. Review slide This table doesn’t include all the factors we talked about earlier. There are situations that will arise that might warrant modifying the onset of infectious period to an earlier date than what is recommended in this table such as if: There is evidence of TB transmission among contacts with significant exposure only in early part of the original infectious period and/or There is evidence of significant transmission in the original infectious period (e.g., high TST conversion rate), particularly if the patient’s symptom onset history is questionable and/or the patient’s clinical presentation suggests advanced TB disease (cavitation, disseminated TB, severe wasting, etc.). Onset of infectious period should be given a specific date (e.g. April 15, 2008 vs. April 2008). This date may change as new information is obtained during the course of the investigation. TABLE 2. Guidelines for estimating the beginning of the period of infectiousness of persons with tuberculosis (TB), by index case characteristic. Guidelines for the Investigation of Contacts of Persons with Infectious Tuberculosis. Recommendations from the National Tuberculosis Controllers Association and CDC. 2005.

Sample Contact Roster

References and Resources Patient interview guide Available upon request from the TB Branch CTCA Contact Investigation guidelines https://ctca.org/guidelines/cdph-ctca-joint-guidelines/ Rutgers TB Center of Excellence materials http://globaltb.njms.rutgers.edu/educationalmaterials/productlist. php CDPH TB Control Branch staff: Anne Cass: anne.cass@cdph.ca.gov Stephanie Spencer: stephanie.spencer@cdph.ca.gov